市場調査レポート

商品コード

1593751

双極性障害市場：タイプ別、薬剤クラス別、障害タイプ別、投与経路別、流通チャネル別、地域別、機会、予測、2017年～2031年

Bipolar Disorder Market Assessment, By Type, By Drug Class, By Disorder Type, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年11月20日
発行: Market Xcel - Markets and Data
ページ情報: 英文 233 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 660,690円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 836,874円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,203,924円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の双極性障害の市場規模は、予測期間の2024年～2031年のCAGRが3.01％となり、2023年の50億1,000万米ドルから2031年には63億5,000万米ドルに成長すると予測されています。双極性障害市場の成長は、世界の双極性障害の疾病負担の増加、メンタルヘルスに対する関心の高まり、早期かつ効果的な診断のための診断方法の増加、市場参入企業の革新的な製品提供などの要因によって促進されると予測されます。

双極性障害は、躁病やうつ病のエピソードを含む極端な気分の変動を特徴とする精神疾患です。治療には通常、気分安定薬や抗精神病薬などの薬物療法と、認知行動療法（CBT）などの心理療法が組み合わされます。個別化されたアプローチが不可欠であり、多くの場合、症状の効果的な管理を助けるために生活様式の変化や支援システムを取り入れます。定期的なモニタリングと治療計画の調整は、双極性障害の安定を達成し、生活の質を向上させるために極めて重要です。双極性障害の治療薬市場は、メンタルヘルスが重視されるようになり、精神的な健康が注目されるようになったことから、増加傾向にあります。精神疾患にまつわる偏見が払拭され、より良い治療の機会が開かれつつあります。ウェアラブルデバイスや人工知能のようなデジタルツールを活用した早期診断法が、市場の成長をさらに後押ししています。この市場における主な課題は、治療期間の長期化と患者の服薬アドヒアランスです。しかし、より良い代替品を提供しようとする市場参入企業の努力により、市場の成長は上昇を続けています

当レポートでは、世界の双極性障害市場について調査し、市場の概要とともに、タイプ別、薬剤クラス別、障害タイプ別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

市場リーダートップ5の競合マトリックス
参入企業トップ5のSWOT分析
市場参入企業トップ10の情勢
- AbbVie Inc.
- GlaxoSmithKline plc
- Eli Lilly and Company
- Janssen Pharmaceuticals, Inc.
- Astellas Pharma Inc.
- Bristol Myers Squibb Company
- Pfizer Inc.
- Novartis AG
- Otsuka Pharmaceutical Co., Ltd.
- AstraZeneca PLC

第21章戦略的提言

第22章お問い合わせと免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 3. Global Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 4. Global Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 5. Global Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 6. Global Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 7. Global Bipolar Disorder Market Share (%), By Region, 2017-2031F
Figure 8. North America Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 9. North America Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 10. North America Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 11. North America Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 12. North America Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 13. North America Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 14. North America Bipolar Disorder Market Share (%), By Country, 2017-2031F
Figure 15. United States Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 16. United States Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 17. United States Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 18. United States Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 19. United States Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 20. United States Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 21. Canada Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 22. Canada Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 23. Canada Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 24. Canada Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 25. Canada Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 26. Canada Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 27. Mexico Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 28. Mexico Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 29. Mexico Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 30. Mexico Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 31. Mexico Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 32. Mexico Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 33. Europe Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 34. Europe Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 35. Europe Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 36. Europe Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 37. Europe Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 38. Europe Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 39. Europe Bipolar Disorder Market Share (%), By Country, 2017-2031F
Figure 40. Germany Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 41. Germany Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 42. Germany Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 43. Germany Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 44. Germany Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 45. Germany Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 46. France Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 47. France Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 48. France Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 49. France Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 50. France Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 51. France Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 52. Italy Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 53. Italy Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 54. Italy Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 55. Italy Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 56. Italy Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 57. Italy Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 58. United Kingdom Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 59. United Kingdom Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 60. United Kingdom Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 61. United Kingdom Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 62. United Kingdom Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 63. United Kingdom Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 64. Russia Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 65. Russia Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 66. Russia Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 67. Russia Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 68. Russia Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 69. Russia Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 70. Netherlands Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 71. Netherlands Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 72. Netherlands Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 73. Netherlands Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 74. Netherlands Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 75. Netherlands Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 76. Spain Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 77. Spain Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 78. Spain Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 79. Spain Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 80. Spain Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 81. Spain Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 82. Turkey Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 83. Turkey Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 84. Turkey Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 85. Turkey Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 86. Turkey Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 87. Turkey Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 88. Poland Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 89. Poland Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 90. Poland Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 91. Poland Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 92. Poland Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 93. Poland Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 94. South America Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 95. South America Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 96. South America Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 97. South America Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 98. South America Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 99. South America Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 100. South America Bipolar Disorder Market Share (%), By Country, 2017-2031F
Figure 101. Brazil Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 102. Brazil Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 103. Brazil Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 104. Brazil Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 105. Brazil Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 106. Brazil Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 107. Argentina Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 108. Argentina Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 109. Argentina Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 110. Argentina Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 111. Argentina Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 112. Argentina Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 113. Asia-Pacific Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 114. Asia-Pacific Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 115. Asia-Pacific Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 116. Asia-Pacific Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 117. Asia-Pacific Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 118. Asia-Pacific Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 119. Asia-Pacific Bipolar Disorder Market Share (%), By Country, 2017-2031F
Figure 120. India Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 121. India Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 122. India Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 123. India Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 124. India Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 125. India Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 126. China Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 127. China Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 128. China Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 129. China Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 130. China Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 131. China Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 132. Japan Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 133. Japan Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 134. Japan Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 135. Japan Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 136. Japan Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 137. Japan Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 138. Australia Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 139. Australia Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 140. Australia Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 141. Australia Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 142. Australia Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 143. Australia Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 144. Vietnam Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 145. Vietnam Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 146. Vietnam Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 147. Vietnam Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 148. Vietnam Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 149. Vietnam Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 150. South Korea Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 151. South Korea Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 152. South Korea Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 153. South Korea Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 154. South Korea Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 155. South Korea Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 156. Indonesia Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 157. Indonesia Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 158. Indonesia Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 159. Indonesia Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 160. Indonesia Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 161. Indonesia Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 162. Philippines Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 163. Philippines Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 164. Philippines Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 165. Philippines Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 166. Philippines Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 167. Philippines Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 168. Middle East & Africa Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 169. Middle East & Africa Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 170. Middle East & Africa Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 171. Middle East & Africa Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 172. Middle East & Africa Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 173. Middle East & Africa Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 174. Middle East & Africa Bipolar Disorder Market Share (%), By Country, 2017-2031F
Figure 175. Saudi Arabia Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 176. Saudi Arabia Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 177. Saudi Arabia Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 178. Saudi Arabia Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 179. Saudi Arabia Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 180. Saudi Arabia Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 181. UAE Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 182. UAE Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 183. UAE Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 184. UAE Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 185. UAE Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 186. UAE Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 187. South Africa Bipolar Disorder Market, By Value, In USD Billion, 2017-2031F
Figure 188. South Africa Bipolar Disorder Market Share (%), By Type, 2017-2031F
Figure 189. South Africa Bipolar Disorder Market Share (%), By Drug Class, 2017-2031F
Figure 190. South Africa Bipolar Disorder Market Share (%), By Disorder Type, 2017-2031F
Figure 191. South Africa Bipolar Disorder Market Share (%), By Route of Administration, 2017-2031F
Figure 192. South Africa Bipolar Disorder Market Share (%), By Distribution Channel, 2017-2031F
Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 194. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 195. By Disorder Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 196. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX12263

Global bipolar disorder market is projected to witness a CAGR of 3.01% during the forecast period 2024-2031, growing from USD 5.01 billion in 2023 to USD 6.35 billion in 2031. The growth in the bipolar disorder market is anticipated to be fueled by factors like the growing disease burden of bipolar disorder worldwide, growing concerns about mental health, increased diagnostics methods for early and effective diagnosis coupled with innovative product offerings from market players.

Bipolar disorder is a mental health condition characterized by extreme mood swings, including episodes of mania and depression. Treatment typically involves a combination of medications, such as mood stabilizers and antipsychotics, and psychotherapy, including cognitive behavioral therapy (CBT). A personalized approach is essential, often incorporating lifestyle changes and support systems to help manage symptoms effectively. Regular monitoring and adjustments to the treatment plan are crucial for achieving stability and improving the quality of life for individuals with bipolar disorders. The market for pharmaceutical treatment options for bipolar disorder is on the rise owing to increased emphasis on mental health and attention being given to mental wellness these days. The stigma associated with mental diseases is now clearing up, thus opening the door to opportunities for better treatment. Early diagnostic methods that utilize digital tools like wearable devices and artificial intelligence further drive the growth in the market. The major challenge in this market is the longer duration of treatment and patient adherence to it. However, the efforts of market players to provide better alternatives keep market growth on the rise. For instance, in April 2024, Vanda Pharmaceuticals Inc. received FDA approval for its atypical antipsychotic Fanapt (iloperidone) to treat manic or mixed episodes in adults with bipolar I disorder. Based on a Phase III clinical trial involving around 400 patients, this approval demonstrated significant improvements in mania severity compared to placebo. Fanapt, previously approved for schizophrenia, offers flexible dosing and a well-established safety profile.

Growing Bipolar Disease Burden to Boost Market Demand

The rising tide of bipolar disorder has a profound implication on the demand side of this market for therapeutics. Growing awareness and more developed diagnostic practices have increased the prevalence, so more patients find treatment. Extreme mood swings characterize bipolar disorder; hence the condition continues to create continuous demand for mood stabilizers, antipsychotics, and psychotherapy. Increased loss of productivity and healthcare costs attributable to the disorder have made governments and organizations concentrate more on initiatives that improve mental health, thus pushing the growth rate even higher in the market. Advances in research and development have also resulted in novel therapies that are effective and attractive to treatment. As acceptance within society of mental health issues improves, more patients are expected to seek help, increasing overall expansion in the bipolar therapeutics market. This mix sets the bipolar disorder market up to have a great future in the coming years. For instance, as per WHO data, more than 40 million patients have bipolar disorder across the globe, and according to the latest Global Burden of Disease (GBD) study, around 2.4% of the global population is affected by bipolar disorder.

Advancements in Diagnostic Tools Drive Market Growth

Advances in diagnostic tools are also a significant growth area in the bipolar disorder market as sophisticated mechanisms increase the precision of their identification and subsequent treatments. Recent developments include a relatively simple blood test, which can diagnose as much as 30% of cases of bipolar disorder-especially in conjunction with online psychiatric assessments. This advance clarifies differences between bipolar disorder and other closely related diagnoses, such as major depressive disorder, often over-diagnosed. With growing awareness and reduced stigma, more patients seek timely diagnoses, thus fueling the market demand. Technological advancement also helps better manage patients by including mood pattern monitoring applications in the patient's smartphone. Increased diagnosis leads to interventions at earlier stages, thus better interventions and, subsequently, more drugs and therapies for the disorder of bipolar. This trend is expected to continue with further research and tools. For instance, in April 2024, SYNLAB International GmbH marked World Bipolar Day 2024 by announcing the launch of a revolutionary test for diagnosing bipolar disorder in France. The myEDIT-B test is the first clinically validated test for differentiating between bipolar disorder and unipolar depression, using RNA editing changes in patients' blood.

Mood Stabilizers Segment to Dominate With Highest Market Share

Mood stabilizers are one of the most used medications for bipolar disorder. They are effective in the stabilization of mood swings and the prevention of both manic and depressive episodes, thus holding the major share in the bipolar disorder market. Among all the discovered mood stabilizers, lithium was the first in use to treat patients with mania. It had long been used in the treatment of mania. It was known for its efficacy in reducing the frequency as well as severity of manic episodes with protection against depression. Other drugs have also been effective, the best examples being valproate and lamotrigine, though these are most effective for certain types of bipolar. They stabilize the shifting patterns of mood as much as possible, helping a person stay balanced and permitting daily functioning to improve. Adding further strength to their position as the foundation in bipolar disorder treatment is their ability to improve quality of life and prevent recurrence. For instance, several mood stabilizer drugs approved by USFDA in recent times include Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Aripiprazole (Abilify), Lurasidone (Latuda), Asenapine (Saphris), Cariprazine (Vraylar), and Lumateperone (Caplyta).

Asia-Pacific Dominates the Bipolar Disorder Market

Asia-Pacific is anticipated to register a fast CAGR and, thus, exponential growth. Compared to the historical years, the diagnosis and recognition of mental health conditions are more prevalent in Asia-Pacific now, thereby increasing the demand for efficient treatment options significantly. In addition, with the effect of continuous urbanization and a change in lifestyle increasing stress factors, more people are now approaching health professionals for solutions to these mental health issues. Improved governmental initiatives and a boost in healthcare infrastructure are also increasing psychiatric services and medications. At the same time, the Asia-Pacific region is witnessing increasing investment from pharmaceutical companies that focus on the research and development of new therapies targeted at the peculiar needs of diverse populations. Mental health is slowly eroding its stigma, and more patients are encouraged to seek treatment. As such, these factors make the Asia-Pacific market for bipolar disorder treatment a rising area and an attractive investment opportunity for stakeholders in the healthcare industry. For instance, according to the National Mental Health Survey conducted in India, the prevalence of bipolar disorder in India is 0.5%, which comes out to be affecting more than 7 million people in India.

Future Market Scenario (2024-2031F)

The rise of digital therapeutics and online cognitive behavioral therapy (CBT) offers accessible, effective management tools for patients. These platforms can reduce depressive symptoms and improve overall well-being by providing real-time support and monitoring.

Devices that monitor sleep patterns and physical activity are proving effective in managing symptoms. Research indicates that regular tracking of these factors can stabilize mood, leading to more tailored treatment approaches.

Discoveries related to specific genes, like AKAP11, provide a deeper understanding of bipolar disorder's molecular mechanisms, paving the way for novel therapies that target these pathways.

Key Players Landscape and Outlook

The market for pharmaceuticals for bipolar disorder is being catered to by several players ranging from small startups to global pharmaceutical giants. Recent market activities include innovative product launches, acquisition deals, and regulatory approvals, which are anticipated to expand the market in the forecast period.

In March 2024, Bristol Myers Squibb (BMS) completed its acquisition of Karuna Therapeutics, broadening its neuroscience portfolio. This strategic move includes the integration of KarXT (xanomeline-trospium), an innovative antipsychotic with a unique mechanism of action, which is currently under review for treating schizophrenia. Notably, KarXT is also in trials for additional indications, including Bipolar I disorder, and agitation associated with Alzheimer's disease, highlighting its potential to address a range of mental health conditions. The acquisition is expected to bolster BMS's growth trajectory, aligning with its commitment to expanding treatment options in neuroscience.

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Bipolar Disorder Market Outlook, 2017-2031F

4.1. Market Size Analysis & Forecast
- 4.1.1. By Value
4.2. Market Share Analysis & Forecast
- 4.2.1. By Type
  - 4.2.1.1. Generic
  - 4.2.1.2. Branded
- 4.2.2. By Drug Class
  - 4.2.2.1. Mood Stabilizer
  - 4.2.2.2. Anticonvulsants
  - 4.2.2.3. Anti-Psychotic Drugs
  - 4.2.2.4. Anti-Depressant Drugs
  - 4.2.2.5. Anti-Anxiety Drugs
- 4.2.3. By Disorder Type
  - 4.2.3.1. Bipolar I Disorder
  - 4.2.3.2. Bipolar II Disorder
  - 4.2.3.3. Cyclothymic Disorder
- 4.2.4. By Route of Administration
  - 4.2.4.1. Oral
  - 4.2.4.2. Parenteral
- 4.2.5. By Distribution Channel
  - 4.2.5.1. Hospital Pharmacies
  - 4.2.5.2. Retail Pharmacies
  - 4.2.5.3. Online Pharmacies
- 4.2.6. By Region
  - 4.2.6.1. North America
  - 4.2.6.2. Europe
  - 4.2.6.3. Asia-Pacific
  - 4.2.6.4. South America
  - 4.2.6.5. Middle East and Africa
- 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
4.3. Market Map Analysis, 2023
- 4.3.1. By Type
- 4.3.2. By Drug Class
- 4.3.3. By Disorder Type
- 4.3.4. By Route of Administration
- 4.3.5. By Distribution Channel
- 4.3.6. By Region

5. North America Bipolar Disorder Market Outlook, 2017-2031F*

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Type
  - 5.2.1.1. Generic
  - 5.2.1.2. Branded
- 5.2.2. By Drug Class
  - 5.2.2.1. Mood Stabilizer
  - 5.2.2.2. Anticonvulsants
  - 5.2.2.3. Anti-Psychotic Drugs
  - 5.2.2.4. Anti-Depressant Drugs
  - 5.2.2.5. Anti-Anxiety Drugs
- 5.2.3. By Disorder Type
  - 5.2.3.1. Bipolar I Disorder
  - 5.2.3.2. Bipolar II Disorder
  - 5.2.3.3. Cyclothymic Disorder
- 5.2.4. By Route of Administration
  - 5.2.4.1. Oral
  - 5.2.4.2. Parenteral
- 5.2.5. By Distribution Channel
  - 5.2.5.1. Hospital Pharmacies
  - 5.2.5.2. Retail Pharmacies
  - 5.2.5.3. Online Pharmacies
- 5.2.6. By Country Share
  - 5.2.6.1. United States
  - 5.2.6.2. Canada
  - 5.2.6.3. Mexico
5.3. Country Market Assessment
- 5.3.1. United States Bipolar Disorder Market Outlook, 2017-2031F*
  - 5.3.1.1. Market Size Analysis & Forecast
    - 5.3.1.1.1. By Value
  - 5.3.1.2. Market Share Analysis & Forecast
    - 5.3.1.2.1. By Type
      - 5.3.1.2.1.1. Generic
      - 5.3.1.2.1.2. Branded
    - 5.3.1.2.2. By Drug Class
      - 5.3.1.2.2.1. Mood Stabilizer
      - 5.3.1.2.2.2. Anticonvulsants
      - 5.3.1.2.2.3. Anti-Psychotic Drugs
      - 5.3.1.2.2.4. Anti-Depressant Drugs
      - 5.3.1.2.2.5. Anti-Anxiety Drugs
    - 5.3.1.2.3. By Disorder Type
      - 5.3.1.2.3.1. Bipolar I Disorder
      - 5.3.1.2.3.2. Bipolar II Disorder
      - 5.3.1.2.3.3. Cyclothymic Disorder
    - 5.3.1.2.4. By Route of Administration
      - 5.3.1.2.4.1. Oral
      - 5.3.1.2.4.2. Parenteral
    - 5.3.1.2.5. By Distribution Channel
      - 5.3.1.2.5.1. Hospital Pharmacies
      - 5.3.1.2.5.2. Retail Pharmacies
      - 5.3.1.2.5.3. Online Pharmacies
- 5.3.2. Canada
- 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Bipolar Disorder Market Outlook, 2017-2031F

6.1. Germany
6.2. France
6.3. Italy
6.4. United Kingdom
6.5. Russia
6.6. Netherlands
6.7. Spain
6.8. Poland

7. Asia-Pacific Bipolar Disorder Market Outlook, 2017-2031F

7.1. India
7.2. China
7.3. Japan
7.4. Australia
7.5. Vietnam
7.6. South Korea
7.7. Indonesia
7.8. Philippines

8. South America Bipolar Disorder Market Outlook, 2017-2031F

8.1. Brazil
8.2. Argentina

9. Middle East and Africa Bipolar Disorder Market Outlook, 2017-2031F

9.1. Saudi Arabia
9.2. UAE
9.3. South Africa
9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

15.1. Market Drivers
15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

17.1. Clinical Trials
17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

20.1. Competition Matrix of Top 5 Market Leaders
20.2. SWOT Analysis for Top 5 Players
20.3. Key Players Landscape for Top 10 Market Players
- 20.3.1. AbbVie Inc.
  - 20.3.1.1. Company Details
  - 20.3.1.2. Key Management Personnel
  - 20.3.1.3. Products and Services
  - 20.3.1.4. Financials (As Reported)
  - 20.3.1.5. Key Market Focus and Geographical Presence
  - 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 20.3.2. GlaxoSmithKline plc
- 20.3.3. Eli Lilly and Company
- 20.3.4. Janssen Pharmaceuticals, Inc.
- 20.3.5. Astellas Pharma Inc.
- 20.3.6. Bristol Myers Squibb Company
- 20.3.7. Pfizer Inc.
- 20.3.8. Novartis AG
- 20.3.9. Otsuka Pharmaceutical Co., Ltd.
- 20.3.10. AstraZeneca PLC

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

双極性障害市場：タイプ別、薬剤クラス別、障害タイプ別、投与経路別、流通チャネル別、地域別、機会、予測、2017年～2031年

Bipolar Disorder Market Assessment, By Type, By Drug Class, By Disorder Type, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の双極性障害市場の見通し、2017年～2031年

第5章 北米の双極性障害市場の見通し、2017年～2031年

第6章 欧州の双極性障害市場の見通し、2017年～2031年

第7章 アジア太平洋の双極性障害市場の見通し、2017年～2031年

第8章 南米の双極性障害市場の見通し、2017年～2031年

第9章 中東・アフリカの双極性障害市場の見通し、2017年～2031年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

第18章 特許の情勢

第19章 ケーススタディ

第20章 競合情勢

第21章 戦略的提言

第22章 お問い合わせと免責事項

List of Tables

List of Figures

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Bipolar Disorder Market Outlook, 2017-2031F

5. North America Bipolar Disorder Market Outlook, 2017-2031F*

6. Europe Bipolar Disorder Market Outlook, 2017-2031F

7. Asia-Pacific Bipolar Disorder Market Outlook, 2017-2031F

8. South America Bipolar Disorder Market Outlook, 2017-2031F

9. Middle East and Africa Bipolar Disorder Market Outlook, 2017-2031F

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

16. Market Trends and Developments

17. Regulatory Framework and Innovation

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

21. Strategic Recommendations

22. About Us and Disclaimer

第1章プロジェクトの範囲と定義

第2章調査手法

第3章エグゼクティブサマリー

第4章世界の双極性障害市場の見通し、2017年～2031年

第5章北米の双極性障害市場の見通し、2017年～2031年

第6章欧州の双極性障害市場の見通し、2017年～2031年

第7章アジア太平洋の双極性障害市場の見通し、2017年～2031年

第8章南米の双極性障害市場の見通し、2017年～2031年

第9章中東・アフリカの双極性障害市場の見通し、2017年～2031年

第10章需要供給分析

第11章バリューチェーン分析

第12章ポーターのファイブフォース分析

第14章価格分析

第15章市場力学

第16章市場の動向と発展

第17章規制枠組みとイノベーション

第18章特許の情勢

第19章ケーススタディ

第20章競合情勢

第21章戦略的提言

第22章お問い合わせと免責事項